**S4 Table.** Post-consolidation: high risk

| Drug                          | Dose                                                   | Days                  |
|-------------------------------|--------------------------------------------------------|-----------------------|
| **Interim maintenance (11 wk)** |                                                        |                       |
| Vincristine (IV)              | 1.5 mg/m² (max. 2 mg)                                  | 1, 15, 29             |
| Methotrexate (IV)             | 5 g/m²                                                 | 1, 15, 29             |
| HD-Cytarabine (IV)            | 3 g/m² (q 12 hours)                                   | 43, 44                |
| l-Asparaginase (IM)           | 6,000 u/m² (max, 10,000 u)                             | 44                    |
| 6-Mercaptopurine (PO)         | 60 mg/m²                                               | 64 - 77               |
| Methotrexate (IT)             |                                                        |                       |
| **Delayed intensification (8 wk)** |                                                        |                       |
| Vincristine (IV)              | 1.5 mg/m² (max. 2mg)                                  | 1, 15, 29, 43         |
| Daunorubicin (IV)             | 30 mg/m²                                               | 1, 15, 29, 43         |
| Cytarabine (IV)               | 100 mg/m²                                              | 1-5, 29-33            |
| Cyclophosphamide (IV)         | 1,200 mg/m²                                            | 15, 43                |
| l-Asparaginase (IM)           | 6,000 u/m² (max, 10,000 u)                             | 16, 18, 20, 44, 46, 48|
| Prednisolone (PO)             | 45 mg/m² (max. 60 mg)                                  | 1-5, 15-19, 29-33, 43-47|
| Methotrexate (IT)             |                                                        |                       |
| **Interim maintenance-II (6 wk)** |                                                   |                       |
| Vincristine (IV)              | 1.5 mg/m² (max. 2 mg)                                  | 1, 22                 |
| Methotrexate (IV)             | 500 mg/m²                                              | 1, 22                 |
| Prednisolone (PO)             | 45 mg/m² (max. 60 mg)                                  | 1-5, 22-26            |
| 6-Mercaptopurine (PO)         | 60 mg/m²                                               | 1-42                  |
| Methotrexate (IT)             |                                                        |                       |
| **Delayed intensification-II (7 wk)** |                                                   |                       |
| Vincristine (IV)              | 1.5 mg/m² (max. 2 mg)                                  | 1, 15                 |
| Daunorubicin (IV)             | 30 mg/m²                                               | 1, 15                 |
| Cytarabine (IV)               | 100 mg/m²                                              | 1-5                   |
| Cyclophosphamide (IV)         | 1,200 mg/m²                                            | 15                    |
| l-Asparaginase (IM)           | 6,000 u/m² (max, 10,000 u)                             | 16, 18, 20, 30        |
| Prednisolone (PO)             | 45 mg/m² (max. 60 mg)                                  | 1-5, 15-19            |
| HD-Cytarabine (IV)            | 3 g/m² (q 12 hours)                                   | 29, 30                |
| Methotrexate (IT)             |                                                        | 1, 29                 |

Schema: IM#1 (HD-MTX x3, HD-Ara x1) → DI#1 → IM#2 (ID-MTX x2) → DI#2 → Maint. DI, delayed intensification; HD-Ara, high dose cytarabine; HD-MTX, high dose methotrexate; IM,
intramuscular; IT, intrathecal; IV, intravenous; Maint., maintenance; PO, per os. a) Age-adjusted doses of intrathecal methotrexate: 6 mg (<1 year), 7.5 mg (≥ 1 and < 2 years), 10 mg (≥ 2 and < 3 years), 12.5 mg (≥ 3 years).